Michael C. Heinrich, M.D.
Dr. Heinrich's research includes both preclinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. This includes both genomics research using high-throughput gentoyping to identify oncogenic mutations and testing of new compounds in cellular and biochemical assays. Dr. Heinrich’s laboratory is particularly expert in the analysis of inhibitors of oncogenic receptor tyrosine kinases such as KIT, PDGFRA and FLT3.
Summary of Current Research
Additional special interests
Development of novel tyrosine kinase inhibitors for treatment of human cancers
"Combination therapy for KIT-mutant mast cells: Targeting constitutive NFAT and KIT activity,"
"Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer,"
"Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST),"
"Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract,"
"Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial,"